Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) from Japan and South Korea.Methods In this phase III, open-label continuation study (BEL114333; NCT01597622), eligible completers of BEL113750 (NCT01345253) or BEL112341 (NCT0148...

Full description

Bibliographic Details
Main Authors: Damon Bass, Regina Kurrasch, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/7/2/e001629.full

Internet

https://rmdopen.bmj.com/content/7/2/e001629.full

Similar Items